DB05730ExperimentalSmall molecule
PMI-001 is a stand-alone, disease-modifying, anti-rheumatic drug (DMARD) being developed by Phytomedics Inc. It is an extract of the roots of an undisclosed perennial shrub which interferes with the production...
- Mechanism
- Curator reviewed
PMI-001 exerts its potent anti-inflammatory and immunosuppressant activities through unique and synergistic modes of action, which involves potent inhibition of several families of pro-inflammatory genes. PMI-001 most likely interferes with the production of IL-2 and COX-2 proteins.
- Primary indication
- Investigated for use/treatment in rheumatoid arthritis.Curator reviewed
- Code names
- PMI-001
Resolves to
Compound
Which companies are running trials of PMI-001, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account